|
André Choulika, PhD in molecular virology is Chairman and Chief Executive Officer of the Cellectis Group that he co-founded in 1999. ==Biography== Born on January 23, 1965 in Beirut, André Choulika started his studies in 1985 in biochemistry and genetic at Pierre and Marie Curie University (Paris VI) and joined Professor Bernard Dujon’s lab. He discovered meganucleases, which are highly specific « DNA scissors ». André Choulika is a pioneer in the analysis and use of meganucleases to modify complex genomes. He did his DEA thesis at the Institut Pasteur in François Jacob's laboratory, 1965 Nobel Prize in medicine. After receiving his doctorate in molecular virology from Pierre and Marie Curie University-Paris VI, André Choulika completed a research fellowship in the Harvard Medical School Department of Genetics in Boston. Later, while working in the Division of Molecular Medicine at Boston Children’s Hospital, he developed the first approaches to meganuclease-based human gene therapy. In 1999, he won with his project Cellectis, the first national competition organized by Claude Allègre (French Ministry of Research) to help business start-up projects in innovative technologies. Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). Since 2009, André Choulika is also member of the Supervisory Board of Viroxis SA, member of the Investment Committee of G1J Ile-de-France, Council member of ARIIS, Council member of EuropaBio and member of the Scientific Advisory Board of Biofutur. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「André Choulika」の詳細全文を読む スポンサード リンク
|